ESMO INITIATIVES
![Doctors_Discussing_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/aaa_generic-pictures-stock/doctors_discussing/doctors_discussing_02/19301489-1-eng-GB/doctors_discussing_02_i770.jpg)
How to interpret genomic testing results? ESMO recommendations to make reports easy to read
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
Oncologists do not feel well-prepared to address the health needs of LGBTQ cancer patients
In an ESMO-SIOPE survey, only 10% of respondents report they received adequate education in medical school about how to tailor cancer care to this population
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
LATEST NEWS
![Hospital_04](/var/esmo/storage/images/media/esmo-daily-reporter/images/aaa_generic-pictures-stock/hospital_patients/hospital_04/18862138-1-eng-GB/hospital_04_i770.jpg)
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
The promise of immuno-oncology in the neoadjuvant setting
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
FROM GUEST EDITORS
![Editorial_GI](/var/esmo/storage/images/media/esmo-daily-reporter/images/editorials/editorial_gi/18280011-1-eng-GB/editorial_gi_i770.jpg)
Why are gastrointestinal cancer patients getting younger?
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
The promises of antibody-drug conjugates for ovarian cancer
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
The growing role of AI in breast cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes